Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Enterprise Value (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Enterprise Value for 16 consecutive years, with -$6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 49.2% to -$6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.8 million, a 49.2% decrease, with the full-year FY2024 number at -$4.1 million, up 4.09% from a year prior.
  • Enterprise Value was -$6.8 million for Q3 2025 at Harvard Bioscience, up from -$7.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$3.8 million in Q1 2023 to a low of -$7.8 million in Q4 2021.
  • A 5-year average of -$5.2 million and a median of -$5.1 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: plummeted 137.24% in 2021, then surged 42.36% in 2022.
  • Harvard Bioscience's Enterprise Value stood at -$7.8 million in 2021, then soared by 42.36% to -$4.5 million in 2022, then rose by 4.99% to -$4.3 million in 2023, then increased by 4.09% to -$4.1 million in 2024, then crashed by 65.94% to -$6.8 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Enterprise Value are -$6.8 million (Q3 2025), -$7.4 million (Q2 2025), and -$5.5 million (Q1 2025).